NPCE
The quarter had a nice little tailwind
NeuroPace said first-quarter revenue hit $22.1 million, with ex-DIXI Medical sales coming in at $22.0 million — up 20.1% year over year. That’s not just “we beat last year by a bit” growth; it’s the kind of number that suggests the core RNS System business is still finding traction.
Why investors should care
For a medical-device name like NeuroPace, the market usually cares about two things: is the product actually getting adopted, and is management confident enough to raise the bar? On both counts, this update checks the box. Higher revenue guidance for 2026 tells you the company sees momentum continuing, which is a better vibe than the usual earnings-call fog machine.
The not-so-secret sauce
The company said RNS System revenue was $21.7 million in the quarter, which means the epilepsy-focused implant is still doing the heavy lifting. If you’ve been watching NPCE, this is the classic “show me the growth, then show me the follow-through” moment.
Big picture
NeuroPace isn’t trying to be everything to everyone. It’s trying to make one very specific therapy more common, more reimbursed, and more durable as a business. And for now, the numbers say that plan is still alive and kicking.